Cell-based medicinal products: Progress and perspectives

Authors

• Lijian HUI, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China
• Xiang YUAN, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China
• Jingqi WU, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China

Keywords

Cell-based medicinal products, cell manufacture, cell therapy

Abstract

Cell-based medicinal products are a breakthrough that has been proven to treat previously incurable diseases, making them a topic of global interest. This review delves into the current state and progress of cell therapy, highlighting the remarkable therapeutic effects of various types of cell-based medicinal products. We specifically explore the potential development of cell-based medicinal products in China, focusing on promoting clinical translation and commercialization. We propose necessary actions to achieve these goals, such as fostering cutting-edge basic research, innovative therapeutic approaches, scalable manufacturing processes, and policy changes.

First page

1434

Last Page

1446

Language

Chinese

Publisher

Bulletin of Chinese Academy of Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.

References

1 惠利健. 细胞治疗药物：基于作用机制的研究和应用. 中国科学：生命科学, 2023, 53(8): 1067-1071.Hui L J. Cell-based medicine: Mode-of-action-based research and application. Scientia Sinica (Vitae), 2023, 53 (8): 1067-1071. (in Chinese)

2 Williams J Z, Allen G M, Shah D, et al. Precise T cell recognition programs designed by transcriptionally linking multiple receptors. Science, 2020, 370: 1099-1104.

3 Lajoie M J, Boyken S E, Salter A I, et al. Designed protein logic to target cells with precise combinations of surface antigens. Science, 2020, 369: 1637-1643.

4 Tousley A M, Rotiroti M C, Labanieh L, et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature, 2023, 615: 507-516.

5 He C H, Mansilla-soto J, Khanra N, et al. CD19 CAR antigen engagement mechanisms and affinity tuning. Science Immunology, 2023, 8: eadf1426.

6 Foster M C, Savoldo B, Lau W, et al. Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity. Blood, 2021, 137(23): 3306-3309.

7 Labanieh L, Majzner R G, Klysz D, et al. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell, 2022, 185(10): 1745-1763.

8 Li H S, Wong N M, Tague E, et al. High-performance multiplex drug-gated CAR circuits. Cancer Cell, 2022, 40 (11): 1294-1305.

9 Liu Y, Liu G N, Wang J S, et al. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Science Translational Medicine, 2021, 13: eabb5191.

10 Zhang H H, Li F L, Cao J, et al. A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity. Science Translational Medicine, 2021, 13: eaba7308.

11 Li W T, Qiu S Z, Chen J, et al. Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy. Immunity, 2020, 53(2): 456-470.

12 Pecher A C, Hensen L, Klein R, et al. CD19-targeting CAR T cells for Myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA, 2023, 329(24): 2154-2162.

13 Van Oekelen O, Aleman A, Upadhyaya B, et al. Neurocognitive and hypokinetic movement disorder with features of Parkinsonism after BCMA-targeting CAR-T cell therapy. Nature Medicine, 2021, 27(12): 2099-2103.

14 Zhang J Q, Hu Y X, Yang J X, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in BNHL. Nature, 2022, 609: 369-374.

15 An J, Zhang C P, Qiu H Y, et al. Enhancement of the viability of T cells electroporated with DNA via osmotic dampening of the DNA-sensing cGAS-STING pathway. Nature Biomedical Engineering, 2024, 8(2): 149-164.

16 Ghassemi S, Durgin J S, Nunez-Cruz S, et al. Rapid manufacturing of non-activated potent CAR T cells. Nature Biomedical Engineering, 2022, 6(2): 118-128.

17 Wang Y, Chen X D, Cao W, et al. Plasticity of mesenchymal stem cells in immunomodulation: Pathological and therapeutic implications. Nature Immunology, 2014, 15(11): 1009-1016.

18 王瑜, 徐慕晗, 郑凡君, 等. 间充质干细胞在炎症性疾病治疗中的基础研究和临床应用. 中国细胞生物学学报, 2019, 41(4): 561-572.Wang Y, Xu M H, Zheng F J, et al. Immunoregulatory mechanisms and applications of mesenchymal stem/stromal cells in inflammatory diseases. Chinese Journal of Cell Biology, 2019, 41(4): 561-572. (in Chinese)

19 Zhou T, Yuan Z N, Weng J, et al. Challenges and advances in clinical applications of mesenchymal stromal cells. Journal of Hematology & Oncology, 2021, 14(1): 24.

20 Galipeau J, Sensébé L. Mesenchymal stromal cells: Clinical challenges and therapeutic opportunities. Cell Stem Cell, 2018, 22(6): 824-833.

21 Ren G W, Zhang L Y, Zhao X, et al. Mesenchymal stem cellmediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2008, 2(2): 141-150.

22 Zhang Y N, Wang J C, Huang W J, et al. Nuclear Nestin deficiency drives tumor senescence via lamin A/C-dependent nuclear deformation. Nature Communications, 2018, 9(1): 3613.

23 Yang Y K, Ogando C R, Wang S C, et al. Changes in phenotype and differentiation potential of human mesenchymal stem cells aging in vitro. Stem Cell Research & Therapy, 2018, 9(1): 131.

24 Zhang T, He Y Q, Shu X, et al. Photomodulation alleviates cellular senescence of aging adipose-derived stem cells. Cell Communication and Signaling, 2023, 21(1): 146.

25 Yu J Y, Vodyanik M A, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science, 2007, 318: 1917-1920.

26 Hering B J, Bellin M D. Transplantation: Sustained benefits of islet transplants for T1DM. Nature Reviews Endocrinology, 2015, 11(10): 572-574.

27 Millman J R, Xie C H, Van Dervort A, et al. Generation of stem cell-derived β-cells from patients with type 1 diabetes. Nature Communications, 2016, 7: 11463.

28 Pagliuca F W, Millman J R, Gürtler M, et al. Generation of functional human pancreatic beta cells in vitro. Cell, 2014, 159(2): 428-439.

29 Rezania A, Bruin J E, Arora P, et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nature Biotechnology, 2014, 32(11): 1121-1133.

30 Du Y Y, Liang Z, Wang S S, et al. Human pluripotent stemcell-derived islets ameliorate diabetes in non-human Primates. Nature Medicine, 2022, 28(2): 272-282.

31 Cheng X, Ying L, Lu L, et al. Self-renewing endodermal progenitor lines generated from human pluripotent stem cells. Cell Stem Cell, 2012, 10(4): 371-384.

32 Wu J Y, Li T, Guo M, et al. Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue. Cell Discovery, 2024, 10(1): 45.

33 Ma X J, Lu Y K, Zhou Z Y, et al. Human expandable pancreatic progenitor-derived β cells ameliorate diabetes. Science Advances, 2022, 8: eabk1826.

34 Zhu S Y, Russ H A, Wang X J, et al. Human pancreatic betalike cells converted from fibroblasts. Nature Communications, 2016, 7: 10080.

35 Wang Y F, Qin J H, Wang S Y, et al. Conversion of human gastric epithelial cells to multipotent endodermal progenitors using defined small molecules. Cell Stem Cell, 2016, 19(4): 449-461.

36 Wang D S, Wang J Q, Bai L Y, et al. Long-term expansion of pancreatic islet organoids from resident Procr+ progenitors. Cell, 2020, 180(6): 1198-1211.

37 Gornalusse G G, Hirata R K, Funk S E, et al. HLA-Eexpressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nature Biotechnology, 2017, 35(8): 765-772.

38 Vegas A J, Veiseh O, Gürtler M, et al. Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. Nature Medicine, 2016, 22(3): 306-311.

39 Basta G, Montanucci P, Calafiore R. Microencapsulation of cells and molecular therapy of type 1 diabetes mellitus: The actual state and future perspectives between promise and progress. Journal of Diabetes Investigation, 2021, 12(3): 301-309.

40 Obernier K, Alvarez-Buylla A. Neural stem cells: Origin, heterogeneity and regulation in the adult mammalian brain. Development, 2019, 146(4): dev156059.

41 Kim T W, Piao J H, Koo S Y, et al. Biphasic activation of WNT signaling facilitates the derivation of midbrain dopamine neurons from hESCs for translational use. Cell Stem Cell, 2021, 28(2): 343-355.

42 Fitzgerald M, Sotuyo N, Tischfield D J, et al. Generation of cerebral cortical GABAergic interneurons from pluripotent stem cells. Stem Cells, 2020, 38(11): 1375-1386.

43 Wang Y K, Zhu W W, Wu M H, et al. Human clinical-grade parthenogenetic ESC-derived dopaminergic neurons recover locomotive defects of nonhuman primate models of Parkinson’s disease. Stem Cell Reports, 2018, 11(1): 171-182.

44 Kriks S, Shim J W, Piao J H, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature, 2011, 480: 547-551.

45 Kikuchi T, Morizane A, Doi D, et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model. Nature, 2017, 548: 592-596.

46 Schweitzer J S, Song B, Herrington T M, et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson’s disease. New England Journal of Medicine, 2020, 382(20): 1926-1932.

47 Loring J F. Autologous induced pluripotent stem cell-derived neurons to treat Parkinson’s disease. Stem Cells and Development, 2018, 27(14): 958-959.

48 Piao J H, Zabierowski S, Dubose B N, et al. Preclinical efficacy and safety of a human embryonic stem cell-derived midbrain dopamine progenitor product, MSK-DA01.Cell Stem Cell, 2021, 28(2): 217-229.

49 You Z W, Wang L Y, He H, et al. Mapping of clonal lineages across developmental stages in human neural differentiation. Cell Stem Cell, 2023, 30(4): 473-487.

50 Feng L, Li D, Tian Y, et al. One-step cell biomanufacturing platform: Porous gelatin microcarrier beads promote human embryonic stem cell-derived midbrain dopaminergic progenitor cell differentiation in vitro and survival after transplantation in vivo. Neural Regeneration Research, 2024, 19(2): 458-464.

51 Zhang T, Ke W, Zhou X, et al. Human neural stem cells reinforce hippocampal synaptic network and rescue cognitive deficits in a mouse model of Alzheimer’s disease. Stem Cell Reports, 2019, 13(6): 1022-1037.

52 Bershteyn M, Bröer S, Parekh M, et al. Human pallial MGEtype GABAergic interneuron cell therapy for chronic focal epilepsy. Cell Stem Cell, 2023, 30(10): 1331-1350.

53 Curtis E, Martin J R, Gabel B, et al. A first-in-human, phase I study of neural stem cell transplantation for chronic spinal cord injury. Cell Stem Cell, 2018, 22(6): 941-950.

54 Sun Z, Yuan X, Wu J Q, et al. Hepatocyte transplantation: The progress and the challenges. Hepatology Communications, 2023, 7: e0266.

55 Feng S S, Wu J Y, Qiu W L, et al. Large-scale generation of functional and transplantable hepatocytes and cholangiocytes from human endoderm stem cells. Cell Reports, 2020, 33 (10): 108455.

56 Chen S T, Wang J L, Ren H Z, et al. Hepatic spheroids derived from human induced pluripotent stem cells in bioartificial liver rescue porcine acute liver failure. Cell Research, 2020, 30(1): 95-97.

57 Wang S Y, Wang X, Tan Z L, et al. Human ESC-derived expandable hepatic organoids enable therapeutic liver repopulation and pathophysiological modeling of alcoholic liver injury. Cell Research, 2019, 29(12): 1009-1026.

58 Huang P Y, Zhang L D, Gao Y M, et al. Direct reprogramming of human fibroblasts to functional and expandable hepatocytes. Cell Stem Cell, 2014, 14(3): 370-384.

59 Zhang K, Zhang L D, Liu W M, et al. In vitro expansion of primary human hepatocytes with efficient liver repopulation capacity. Cell Stem Cell, 2018, 23(6): 806-819.

60 Fu G B, Huang W J, Zeng M, et al. Expansion and differentiation of human hepatocyte-derived liver progenitorlike cells and their use for the study of hepatotropic pathogens. Cell Research, 2019, 29(1): 8-22.

61 Yuan X, Wu J Q, Sun Z, et al. Preclinical efficacy and safety of encapsulated proliferating human hepatocyte organoids in treating liver failure. Cell Stem Cell, 2024, 31(4): 484-498.

62 Wang Y F, Zheng Q, Sun Z, et al. Reversal of liver failure using a bioartificial liver device implanted with clinicalgrade human-induced hepatocytes. Cell Stem Cell, 2023, 30 (5): 617-631.

63 Li W J, Zhu X J, Yuan T J, et al. An extracorporeal bioartificial liver embedded with 3D-layered human liver progenitor-like cells relieves acute liver failure in pigs. Science Translational Medicine, 2020, 12: eaba5146.

64 Glorioso J M, Mao S A, Rodysill B, et al. Pivotal preclinical trial of the spheroid reservoir bioartificial liver. Journal of Hepatology, 2015, 63(2): 388-398.

Recommended Citation

HUI, Lijian; YUAN, Xiang; and WU, Jingqi (2024) "Cell-based medicinal products: Progress and perspectives," Bulletin of Chinese Academy of Sciences (Chinese Version): Vol. 39 : Iss. 8 , Article 13.
DOI: https://doi.org/10.16418/j.issn.1000-3045.20240221003
Available at: https://bulletinofcas.researchcommons.org/journal/vol39/iss8/13